Lantus, the first peakless basal insulin analogue: 10 years of clinical experience in children and adolescents

This review analyses existing literature, including authors' own data, describing the results of clinical trials which assess safety and efficacy of insulin Glargine (Lantus?) in children and adolescents, as well as peculiar features of T1D management in this age group, including the challenge...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Tamara Leonidovna Kuraeva
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2014
Materias:	t1d children and adolescents insulin glargine glycemic control safety Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/947bfb4adf1b459f8c9e536232bf74b8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:947bfb4adf1b459f8c9e536232bf74b8
record_format	dspace
spelling	oai:doaj.org-article:947bfb4adf1b459f8c9e536232bf74b82021-11-14T09:00:19ZLantus, the first peakless basal insulin analogue: 10 years of clinical experience in children and adolescents2072-03512072-037810.14341/DM20142105-115https://doaj.org/article/947bfb4adf1b459f8c9e536232bf74b82014-07-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/6581https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378This review analyses existing literature, including authors' own data, describing the results of clinical trials which assess safety and efficacy of insulin Glargine (Lantus?) in children and adolescents, as well as peculiar features of T1D management in this age group, including the challenge of reducing the rate of hypoglycemia while maintaining adequate glycemic control. The article also discusses various issues in T1D management in children and adolescents, including the role of glycemic control in development of vascular complications, hypoglycemia and the variability of glycemia. The data confirm the high efficacy of Lantus insulin in respect to metabolic control, including the decrease in the incidence of hypoglycemia and in variability of glycemic profile, the safety of its clinical use in treatment of children, including young children, and adolescents, as well as its ability to improve the quality of life for patients and their parents.Tamara Leonidovna KuraevaEndocrinology Research Centrearticlet1dchildren and adolescentsinsulin glargineglycemic controlsafetyNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 17, Iss 2, Pp 105-115 (2014)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	t1d children and adolescents insulin glargine glycemic control safety Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	t1d children and adolescents insulin glargine glycemic control safety Nutritional diseases. Deficiency diseases RC620-627 Tamara Leonidovna Kuraeva Lantus, the first peakless basal insulin analogue: 10 years of clinical experience in children and adolescents
description	This review analyses existing literature, including authors' own data, describing the results of clinical trials which assess safety and efficacy of insulin Glargine (Lantus?) in children and adolescents, as well as peculiar features of T1D management in this age group, including the challenge of reducing the rate of hypoglycemia while maintaining adequate glycemic control. The article also discusses various issues in T1D management in children and adolescents, including the role of glycemic control in development of vascular complications, hypoglycemia and the variability of glycemia. The data confirm the high efficacy of Lantus insulin in respect to metabolic control, including the decrease in the incidence of hypoglycemia and in variability of glycemic profile, the safety of its clinical use in treatment of children, including young children, and adolescents, as well as its ability to improve the quality of life for patients and their parents.
format	article
author	Tamara Leonidovna Kuraeva
author_facet	Tamara Leonidovna Kuraeva
author_sort	Tamara Leonidovna Kuraeva
title	Lantus, the first peakless basal insulin analogue: 10 years of clinical experience in children and adolescents
title_short	Lantus, the first peakless basal insulin analogue: 10 years of clinical experience in children and adolescents
title_full	Lantus, the first peakless basal insulin analogue: 10 years of clinical experience in children and adolescents
title_fullStr	Lantus, the first peakless basal insulin analogue: 10 years of clinical experience in children and adolescents
title_full_unstemmed	Lantus, the first peakless basal insulin analogue: 10 years of clinical experience in children and adolescents
title_sort	lantus, the first peakless basal insulin analogue: 10 years of clinical experience in children and adolescents
publisher	Endocrinology Research Centre
publishDate	2014
url	https://doaj.org/article/947bfb4adf1b459f8c9e536232bf74b8
work_keys_str_mv	AT tamaraleonidovnakuraeva lantusthefirstpeaklessbasalinsulinanalogue10yearsofclinicalexperienceinchildrenandadolescents
_version_	1718429545818750976

Lantus, the first peakless basal insulin analogue: 10 years of clinical experience in children and adolescents

Ejemplares similares